Ovid Therapeutics Inc. · NASDAQ:OVID

Ovid Therapeutics — Investor Presentation (November 2022)

27 slides from Ovid Therapeutics's investor presentation, November 2022

  1. Slide 1: Ovid Therapeutics Corporate Overview

    TM Ovid Therapeutics Corporate Overview (NASDAQ: OVID) ©2022 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED NOVEMBER 2022

  2. Slide 2: Disclaimers and forward-looking statements

    Disclaimers and forward-looking statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the timing and development of Ovid’s product candidate pipeline and achiev

  3. Slide 3: Transforming the lives of individuals with epilepsies & rare neurological diseases

    Transforming the lives of individuals with epilepsies & rare neurological diseases + Pipeline dedicated to addressing significant unmet + Significant financial interest in need & large addressable development/commercialization market in epilepsies & of soticlestat currently in Phase 3 neurological d

  4. Slide 4: Team of disciplined operators & value creators

    Team of disciplined operators & value creators Transformative transactions • Invested ~$75M in soticlestat for $196M upfront payment and potential milestones of $660M+ and tiered royalties Jeremy Levin Julia Tsai, Ph.D. Claude Nicaise, M.D. Jason Tardio, MBA up to 20% D. Phil, MB BChir Head, Clinica

  5. Slide 5: Advancing epilepsy franchise & genetic seizure programs

    Small molecule Advancing epilepsy franchise & genetic seizure programs Genetic target ANTICIPATED EPILEPSY PROGRAMS INDICATION/TARGET PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MILESTONES OUT-LICENSED TO • Findings from two Dravet syndrome registrational studies SOTICLESTAT CH24H inhibitor • Filing marketi

  6. Slide 6: Epilepsy is a significant & growing market

    Epilepsy is a significant & growing market 3 3 U.S. WORLDWIDE… 30-40% ~65M 1 of individuals with epilepsy have seizures million Patients not controlled with antiepileptic drugs (AED) adults living with epilepsy in the US4 ~6% per year >$8B 2 Branded AED market growth 470,000 ≤17 years Market through

  7. Slide 7: Medicines with novel mechanisms for epilepsies are needed

    Medicines with novel mechanisms for epilepsies are needed Many patients continue to experience seizures despite polypharmacy Seizure-free patients (% of cohort) relative to antiseizure medication use ~30% 60 of epilepsy patients 50 remain treatment-resistant % SEIZURE FREE (OF COHORT) 40 – continuin

  8. Slide 8: Franchise of potentially novel epilepsy medicines

    Franchise of potentially novel epilepsy medicines PRECLINICAL PHASE 1 PHASE 2 PHASE 3 IN-LICENSED OV329 Programs with Potential best-in-class, oral GABA-aminotransferase inhibitor with an enhanced benefit/risk profile and administration in preclinical development for focal seizures, complementary tu

  9. Slide 9: Soticlestat overview

    Actively being studied in two Data to-date suggests potential pivotal, Phase 3 trials use in early treatment lines2 OUT-LICENSED TO TAKEDA (conducted by Takeda): • Based upon promise of seizure • Dravet syndrome (DS) control efficacy and tolerability profile OVERVIEW: observed in clinical trials • L

  10. Slide 10: Soticlestat demonstrated statistically significant seizure reduction in Dravet syndrome

    soticlestat Soticlestat demonstrated statistically significant seizure reduction in Dravet syndrome; numeric reduction in Lennox-Gastaut syndrome1 DRAVET SYNDROME DRAVET SYNDROME(CONVULSIVE SEIZURES) (CONVULSIVE SEIZURES) LENNOX-GASTAUT SYNDROME (DROP SEIZURES) Median Change from Baseline in Seizure

  11. Slide 11: Encouraging safety & tolerability profile ELEKTRA TEAEs

    soticlestat Encouraging safety & tolerability profile ELEKTRA TEAEs OVERALL ADVERSE EVENT RATES TEAEs >5% in soticlestat & 100.00% Soticlestat Placebo >3% difference from (n=71) (n=70) placebo 75.00% Pyrexia 11 (15.5%) 8 (11.4%) 50.00% n=45 25.00% Somnolence 6 (8.5%) 3 (4.3%) 0.00% TEAE Rates SAE Ra

  12. Slide 12: Phase 3 placebo-controlled studies in DS & LGS

    soticlestat Phase 3 placebo-controlled studies in DS & LGS Trials being conducted by Takeda Soticlestat BID Study 1: DS N = 142 (Add-on to SoC) Entry into OLE Placebo BID Study 2: LGS N = 234 (Add-on to SoC) Titration (4 weeks) 1 Maintenance (12 weeks) Full treatment period 16 weeks TRIAL DESIGN OUT

  13. Slide 13: Soticlestat agreement with Takeda holds value of up to $856M

    soticlestat Soticlestat agreement with Takeda holds value of up to $856M1, creating an expected non-dilutive cash stream Invested ~$26M upfront & $57M in clinical development 2021 2025* Est. 2025 and later Upfront payment Expected regulatory milestone Commercial milestones & royalties decision • All

  14. Slide 14: A potent, next-generation GABA-aminotransferase inhibitor

    A potent, next-generation GABA-aminotransferase inhibitor OVERVIEW: Increased potency has potential to deliver: OV329 • Increased seizure reduction efficacy • Improved safety profile (better ocular safety margin than A potential vigabatrin in preclinical studies) anti-seizure • Preferred dosing medi

  15. Slide 15: OV329 is a highly potent GABA-aminotransferase inhibitor

    OV329 OV329 is a highly potent GABA-aminotransferase inhibitor A potential best-in-class GABA-AT inhibitor based on a validated mechanism OPPORTUNITY: with an enhanced benefit/risk profile for treatment-resistant seizures Low GABA transmission (e.g., epilepsy) OV329 facilitates GABA transmission • E

  16. Slide 16: Six preclinical models reaffirm OV329 seizure reduction activity

    OV329 Six preclinical models reaffirm OV329 seizure reduction activity, including resistant seizure models1 Intrahippocampal Kainate Model of Maximal i.v. NMDA-Induced Mesial-Temporal 6 Hz Electrical Electroshock Pentylenetetrazol Infantile Spasm Audiogenic Amygdala Corneal Lobe Epilepsy Stimulation

  17. Slide 17: Daily dosing significantly reduced focal seizures in MTLE model

    OV329 Daily dosing (3 mg/kg) significantly reduced number of focal seizures in MTLE model 30 OV329 BASELINE 25 (3.0 mg/kg PO) (Placebo) 20 HPD Number (per period) 15 *# 10 *** ## Dose 5 # ### ### Baseline ## ** # * * 0 ** Base 0-30min Base 30- Base 60- Base 90- 10-40min 40-70min 70-100min 100-130min

  18. Slide 18: No ocular effects seen following chronic exposure with OV329

    OV329 No ocular effects seen following chronic exposure with OV329 (3 mg/kg) Vehicle OV329 3.0 mg/kg Vigabatrin 300 mg/kg Ocular effects seen in more than No ocular effects seen in 3 mg/kg OV329, q.d. half of rats treated with and vehicle groups in rats at Day 45 Vigabatrin (300 mg/kg) OVID, Data on

  19. Slide 19: Overview: Phase 1 study

    OV329 Overview: Phase 1 study • Design: Single (Part 1) and multiple (Part 2) ascending dose studies gated by cohort • Conducted at Duke University, School of Medicine • Healthy volunteers (6 active; 2 placebo) • 8 volunteers per cohort • First participant expected to be dosed before year-end 2022 •

  20. Slide 20: OV350 & KCC2 direct activators

    Innovative KCC2 activator Franchise in a program program in industry • OV350 & compound library • Consulting support by • Individual compounds potentially OVERVIEW: neuropharmacologist, suitable for: OV350 & KCC2 Prof. Steve Moss • Chemistry & lead identification • IV – acute indications direct cond

  21. Slide 21: KCC2 transporter is central to regulating neuronal inhibition

    OV350 KCC2 transporter is central to regulating neuronal inhibition, potentially reducing seizures1 Healthy Neuron Epileptic Neuron Seizures Potential Effect of OV350 OV350 seeks to directly activate the KCC2 transporter to improve chloride extrusion, thereby reversing neuronal hyperexcitability tha

  22. Slide 22: OV350 preclinical models show rapid, stable accumulation in the brain

    OV350 OV350 preclinical models show rapid, stable accumulation in the brain with a translatable pharmacodynamic biomarker1 KCC2 is expressed exclusively in neurons, OV350 rapidly accumulates in OV350 induces a shift in EEG high unlike other K/Cl co-transporters rodent brain via IV/IP dosing gamma po

  23. Slide 23: In-vivo studies demonstrate mechanistic proof of concept

    OV350 In-vivo studies demonstrate mechanistic proof of concept OV350 restores the efficacy of diazepam to terminate “refractory” Status Epilepticus in preclinical study Adult Mouse Experimental design EEG/EMG Recording Baseline Status Epilepticus Post-Status Epilepticus 1h 2h 2 – 48h Kainic acid 1.

  24. Slide 24: Research collaboration with Gensaic

    Entered early-stage research collaboration with novel, next-generation phage-derived gene delivery platform • Proprietary phage-derived platform (PDP) OVERVIEW • Based upon Nobel-prize winning science for phage display Research PDPs have potential to be: collaboration • Optimal for crossing the bloo

  25. Slide 25: Building value through business development

    Building value through business development Capital from soticlestat licensing deal, coupled with expertise and access, allows for pursuit of successive disciplined and targeted transactions Transaction Goals ` Leverage institutional Complement and enhance Ensure access to key drug delivery epilepsy

  26. Slide 26: Investment highlights

    Investment highlights + Investing in our pipeline and people today to conquer + Strong balance sheet epilepsies and brain disorders tomorrow in cash, cash $137.9M equivalents and marketable securities1 + Epilepsy franchise + Genetic seizure programs shares of common 70.4M stock outstanding2 • 2 smal

  27. Slide 27: Conquer epilepsies & brain disorders with courageous science

    Conquer epilepsies & brain disorders with courageous science ©2022 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 27

Ovid Therapeutics — Investor Presentation (November 2022) on 6ix